This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

AboutAboutEfficacyMOAMist MomentsSafety & DosingSafety &
Dosing
SafetyDosing
PrescribingPrescribingAccess & SavingsZavzpret OneSourcePractice ResourcesPractice ResourcesEventsMaterialsVideosPA Resources
Prescribing InformationPatient Information Instructions for UseIndication Press Release
DosingDosingDosingOne spray in one nostril with no need for priming Dosing information:1
  • Administration is one spray in one nostril with no need for priming
  • ZAVZPRET 10 mg nasal spray is supplied as a ready-to-use,single-dose disposable unit
  • Each carton contains 6 units, meant to treat 6 migraine attacks, as needed
  • Maximum cumulative dose that may be given in a 24-hour period is 10 mg. The safety of treating more than 8 migraines in a 30-day period has not been established
Additional prescribing considerations:1
  • Avoid concomitant administration of ZAVZPRET with drugs that inhibit or induce OATP1B3 or NTCP transporters
  • Avoid use in patients with severe hepatic impairment
  • Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min
  • Can be co-administered with oral contraceptives and antidepressants
  • ZAVZPRET has a half-life of 6.55 hours
See ZAVZPRET in action:

Patient Instructions for Use Video

Watch video Loading
Download Instructions for Use
Safety & Dosing Connect with a sales representative to learn more Request a representative
References:Zavzpret. Package insert. Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0093
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367


​​​​​​​
INDICATION

ZAVZPRETTM (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety Information Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs 1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.

Please click here for full Prescribing Information.
IndicationZAVZPRET™️ (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please see Full Prescribing Information.